Bellinato F, Gisondi P, Girolomoni G, et al. - Exposure to systemic immunosuppressive therapies, comorbidities, and sustained immune activation, especially in the skin, are the factors that could be associated with an increased risk of lymphohematologic malignancies (LHMs), particularly cutaneous T-cell lymphoma, in patients suffering from psoriasis.

• A systematic review and meta-analysis of observational cohort studies was performed.

• Random-effects model was used.

• 25 observational studies with 2,501,652 subjects were analyzed.

• Moderate-to-severe plaque psoriasis was associated with a significantly elevated risk for LHM (hazard ratio [HR], 1.55; 1.24-2.94) and lymphoma (HR, 1.27; 1.08-1.50) vs the general population.

• For Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia, increased risks were evident with HR 1.71, 1.27, 1.32, and 1.28, respectively.

• Cutaneous T-cell lymphoma risk was markedly augmented in psoriasis.